Publicaciones Científicas

Cant. a mostrar
#	Enlaces web
1	FAS and NF-kB signalling modulate dependence of lung cancers on mutant EGFR 24/03/2011
2	Erlotinib versus chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Dr Rafael Rosell et al. Results from the EURTAC trial to assess safety and efficacy of erlotinib vs. standard chemotherapy in first-line treatment of European patients with advanced EGFR-mutation positive NSCLC. The Lancet Oncology, Volume 13, Issue 3, Pages 239 - 246, March 2012
3	Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study 7/03/2011
4	Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced non-small cell lung cancer 01/03/2011
5	Circulating DNA is a useful prognostic factor in advanced non-small-cell lung cancer (NSCLC) patients 01/02/2011
« Inicio Anterior 1 2 3 4 5 Siguiente Fin »
Página 1 de 5

Instituto Oncológico Dr. Rosell